ZA957879B - Combination therapy for hypercholesterolemia - Google Patents

Combination therapy for hypercholesterolemia

Info

Publication number: ZA957879B
Authority: ZA; South Africa
Prior art keywords: hypercholesterolemia; combination therapy; therapy; combination
Prior art date: 1994-09-20

Application number

ZA957879A

Other languages

English (en)

Inventor

Lee A Morehouse

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-20

Filing date

1995-09-19

Publication date

1997-03-19

1995-09-19 Application filed by Pfizer filed Critical Pfizer

1997-03-19 Publication of ZA957879B publication Critical patent/ZA957879B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA957879A 1994-09-20 1995-09-19 Combination therapy for hypercholesterolemia ZA957879B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30890894A	1994-09-20	1994-09-20

Publications (1)

Publication Number	Publication Date
ZA957879B true ZA957879B (en)	1997-03-19

Family

ID=23195885

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA957879A ZA957879B (en)	1994-09-20	1995-09-19	Combination therapy for hypercholesterolemia

Country Status (12)

Country	Link
US (1)	US5807834A (xx)
EP (1)	EP0782451A1 (xx)
JP (1)	JPH09511753A (xx)
AU (1)	AU2453295A (xx)
BR (1)	BR9504072A (xx)
CA (1)	CA2200436A1 (xx)
FI (1)	FI971151A7 (xx)
HR (1)	HRP950488A2 (xx)
IL (1)	IL115310A0 (xx)
MX (1)	MX9702175A (xx)
WO (1)	WO1996009827A2 (xx)
ZA (1)	ZA957879B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7948394A (en) *	1993-12-28	1995-07-17	Pfizer Inc.	Hypocholesterolemic agents
JPH10500702A (ja) *	1994-12-23	1998-01-20	ファイザー・インコーポレーテッド	スクアレンシンテターゼ阻害剤としてのナフチル−ベンゾキサゼピンまたは−ベンゾチアゼピン
US6537987B1 (en) *	1996-06-20	2003-03-25	Pfizer Inc.	4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) *	1996-06-20	1999-10-12	Pfizer Inc.	Squalene synthetase inhibitors
US6352982B1 (en)	1997-04-21	2002-03-05	Takeda Chemical Industries, Ltd.	4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
US6180660B1 (en) *	1997-08-26	2001-01-30	Merck & Co., Inc.	Cholesterol-lowering therapy
US20030153541A1 (en) *	1997-10-31	2003-08-14	Robert Dudley	Novel anticholesterol compositions and method for using same
GB9923076D0 (en)	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
EP1066033B1 (en) *	1998-03-26	2005-12-28	Phytopharm Plc	Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
US6207664B1 (en)	1998-11-25	2001-03-27	Pfizer Inc.	Squalene synthetase inhibitor agents
GB9923078D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
US6465011B2 (en)	1999-05-29	2002-10-15	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6372251B2 (en)	1999-06-11	2002-04-16	Abbott Laboratories	Formulations comprising lipid-regulating agents
GB9923077D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB0000228D0 (en) *	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
US20030092745A1 (en) *	2000-02-25	2003-05-15	Pfizer Inc.	Combination therapy
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (sl)	2001-01-26	2006-10-31	Schering Corp	Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
GB0107822D0 (en) *	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
DK1429756T3 (da)	2001-09-21	2007-03-19	Schering Corp	Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20050130948A1 (en) *	2002-03-27	2005-06-16	Daryl Rees	Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) *	2002-03-27	2012-04-13	파이토팜 피엘씨	사포게닌 및 그 유도체의 치료 방법 및 사용법
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ATE459636T1 (de) *	2002-10-28	2010-03-15	Phytopharm Plc	Stereospezifische reduktion von sapogen-3-onen
US20040092499A1 (en)	2002-11-06	2004-05-13	Schering Corporation	Methods and therapeutic combinations for the treatment of autoimmune disorders
ATE418551T1 (de)	2003-03-07	2009-01-15	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2546601A1 (en)	2003-11-19	2005-06-09	Metabasis Therapeutics, Inc.	Novel phosphorus-containing thyromimetics
WO2005061452A1 (en)	2003-12-23	2005-07-07	Astrazeneca Ab	Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
JP4477474B2 (ja) *	2004-11-15	2010-06-09	株式会社日立製作所	糞便懸濁ろ過用容器
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20100092479A1 (en) *	2008-08-18	2010-04-15	Combinatorx (Singapore) Pte. Ltd.	Compositions and methods for treatment of viral diseases
US20120046364A1 (en)	2009-02-10	2012-02-23	Metabasis Therapeutics, Inc.	Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4602005A (en) *	1982-05-17	1986-07-22	Medical Research Foundation Of Oregon	Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US5063210A (en) *	1989-04-20	1991-11-05	Lange Iii Louis G	Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5629295A (en) *	1992-06-26	1997-05-13	Pfizer Inc.	Steroidal glycosides for treating hypercholesterolemia
LT3300B (en) *	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor

1995
- 1995-06-07 AU AU24532/95A patent/AU2453295A/en not_active Abandoned
- 1995-06-07 EP EP95918721A patent/EP0782451A1/en not_active Withdrawn
- 1995-06-07 FI FI971151A patent/FI971151A7/fi not_active Application Discontinuation
- 1995-06-07 MX MX9702175A patent/MX9702175A/es not_active Application Discontinuation
- 1995-06-07 US US08/793,802 patent/US5807834A/en not_active Expired - Fee Related
- 1995-06-07 WO PCT/IB1995/000447 patent/WO1996009827A2/en not_active Ceased
- 1995-06-07 JP JP8511549A patent/JPH09511753A/ja active Pending
- 1995-06-07 CA CA002200436A patent/CA2200436A1/en not_active Abandoned
- 1995-09-14 IL IL11531095A patent/IL115310A0/xx unknown
- 1995-09-19 BR BR9504072A patent/BR9504072A/pt not_active Application Discontinuation
- 1995-09-19 ZA ZA957879A patent/ZA957879B/xx unknown
- 1995-09-20 HR HR08/308,908A patent/HRP950488A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL115310A0 (en)	1995-12-31
CA2200436A1 (en)	1996-04-04
AU2453295A (en)	1996-04-19
JPH09511753A (ja)	1997-11-25
FI971151A0 (fi)	1997-03-19
FI971151L (fi)	1997-03-19
EP0782451A1 (en)	1997-07-09
WO1996009827A2 (en)	1996-04-04
US5807834A (en)	1998-09-15
FI971151A7 (fi)	1997-03-19
MX9702175A (es)	1997-06-28
WO1996009827A3 (en)	1996-05-23
HRP950488A2 (en)	1997-08-31
BR9504072A (pt)	1996-07-30

Publication	Publication Date	Title
ZA957879B (en)	1997-03-19	Combination therapy for hypercholesterolemia
GB9421709D0 (en)	1994-12-14	Therapeutic compounds
ZA955644B (en)	1997-01-06	Therapeutic compounds
AP2002002661A0 (en)	2002-12-31	Combination therapy for oesteoporosis
GB9415997D0 (en)	1994-09-28	Therapeutic agents
ZA9533B (en)	1995-09-06	Pentolifylline therapy
AUPM695294A0 (en)	1994-08-11	Improved combination therapy dose unit
GB9402641D0 (en)	1994-04-06	Therapeutic agents
GB9600143D0 (en)	1996-03-06	Therapeutic compounds
GB9423682D0 (en)	1995-01-11	Therapeutic agents
GB9401879D0 (en)	1994-03-30	Therapeutic agents
GB9420172D0 (en)	1994-11-23	Therapeutic agents
ZA9711533B (en)	1999-06-22	Therapeutic compounds
GB9403639D0 (en)	1994-04-13	Therapeutic agents
GB9402011D0 (en)	1994-03-30	Therapeutic agents
GB9416629D0 (en)	1994-10-12	Therapeutic compounds
GB9416632D0 (en)	1994-10-12	Therapeutic compounds
SI0769017T1 (en)	2000-08-31	Therapeutic compounds
GB9404379D0 (en)	1994-04-20	Therapeutic improvement
GB9420340D0 (en)	1994-11-23	Therapeutic improvement
GB9505272D0 (en)	1995-05-03	Combination therapy
GB9605525D0 (en)	1996-05-15	Therapy
GB9605466D0 (en)	1996-05-15	Therapy
GB9613017D0 (en)	1996-08-28	Therapeutic compounds
GB9608547D0 (en)	1996-07-03	Therapeutic compounds